Search Results for “Roche” – Page 8 – media

COVID-19 drugs have become a “dark horse”

The success and failure of COVID-19 are the market’s summary of Pfizer in the past few years. In 2022, COVID-19 vaccines and COVID-19 oral drugs brought Pfizer up to $57 billion in revenue. Relying on the wealth brought by COVID-19 products, Pfizer’s revenue exceeded $100 billion this year, setting a new record for the highest revenue of major pharmaceutical companies. However, as the COVID-19 pandemic dissipated, the global market demand for COVID-19 products fell sharply, and Pfizer was the first to bear the brunt. Faced with the “COVID-19 cliff”, Pfizer had to continue to lower its revenue expectations, and the company’s stock price continued to fall. Last year, it fell by more than 40% throughout the year, and its market value evaporated by nearly $130 billion. In this year’s third quarter report, Pfizer handed in a report card that far exceeded market expectations. Revenue in the third quarter reached $17.7 ...
- Source: drugdu
- 47
- November 5, 2024
Domestic TCE polyclonal antibodies are “surging”

MNCs are hunting for domestic molecules and have already involved the field of TCE polyclonal antibodies. On October 29, GlaxoSmithKline announced the acquisition of Enmu Bio’s CD19 and CD20 targeted T cell engager CMG1A46, including a $300 million advance payment and $550 million in potential milestone payments. Not long ago in August, Merck also bought Tongrun Bio’s CD3xCD19 bispecific antibody CN201 with a down payment of $700 million and a milestone payment of $600 million. The direction of the giants is also relatively consistent: betting on the autoimmune market. At present, the core “battlefield” of TCE polyclonal antibodies is tumors. TCE polyclonal antibodies are relatively special. One end (or two ends) is connected to TAA (tumor-associated antigen) to locate tumor cells, and the other end is connected to the CD3 epitope of T cells to activate T cells and exert the tumor-killing effect of T cells. In the field of ...
- Source: drugdu
- 53
- November 2, 2024
Apple’s “killer move” will change the world of diabetes?

Recently, Bloomberg reported that Apple selected some employees to conduct a blood sugar APP test. During the test, the subjects actively monitored their blood sugar through various devices on the market, and then recorded the changes in blood sugar levels caused by food intake. This study may allow Apple to more deeply integrate third-party blood sugar tracking into its own products. Apple has been planning blood sugar monitoring for a long time. In 2010, Jobs led the acquisition of RareLight, a non-invasive blood sugar monitoring company. In 2015, Apple’s frontier exploration department XDG took over the non-invasive blood sugar detection project and has invested a lot of money in recent years for concept verification. In February last year, Apple’s non-invasive blood sugar monitoring project was reported to have a major breakthrough. According to reports, Apple is developing a silicon photonic chip and a measurement process called “optical absorption spectroscopy”, which ...
- Source: drugdu
- 57
- October 30, 2024
When Hengrui Medicine “gave up” going overseas independently

Going overseas is not only a dream, but also a big adventure that Hengrui Medicine has to take. Even under the new measurement standards, there is such a voice that the success of going overseas will be the key to determining whether Hengrui Medicine can maintain its “number one” status. Indeed, Hengrui Medicine, which has accelerated its innovation transformation, has come to a crossroads. First, relying on the domestic market in the past, Hengrui Medicine may not be in a hurry to layout overseas markets. However, with the involution of domestic innovative drugs and pharmaceutical companies going overseas to find incremental growth, internationalization has also been raised to a more important level. Although Hengrui Medicine proposed the direction of “internationalization” as early as in its 2020 annual report, its internationalization has not been smooth in the past few years. Secondly, carrelizumab has already fallen behind, and the internationalization of PD-1 ...
- Source: drugdu
- 65
- October 24, 2024
RNA editing pioneers fought a comeback

“CRISPR gives way, RNA editing therapies are going to speed up.” This is the title of an article published in “Nauter” in February this year (“Move over, CRISPR: RNA-editing therapies pick up steam”). RNA editing technology, which is coming to the fore, is seen as having the potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer there. After years of silence, a ...
- Source: drugdu
- 74
- October 23, 2024
Astellas wins a belated victory

On October 18, the FDA announced the approval of the Claudin18.2 monoclonal antibody Vyloy (zolbetuximab) for marketing, and will use it as the first-line treatment for adult patients with locally advanced unresectable or metastatic gastric cancer with Claudin18.2-positive tumors, and HER2-negative gastroesophageal junction adenocarcinoma. With the announcement of this good news, zolbetuximab officially became the first anti-Claudin18.2 drug approved by the United States. This means that Astellas has taken the lead in this hot target. In the past few years, Claudin18.2 has been a hot target in the field of oncology, attracting the interest of giants such as AstraZeneca, Merck, and Moderna. Of course, the entrants also include many domestic pharmaceutical companies. However, in the face of many entrants, Astellas’s “defending” ability has also been extremely demanding. At present, it may not be easy for it to maintain its leading position. Zolbetuximab has always attracted much attention, and the core ...
- Source: drugdu
- 66
- October 23, 2024
Society for Laboratory Automation and Screening

Organiser：Society for Laboratory Automation and Screening Time：January 25 – 29, 2025 Address：111 W. Harbor Dr., San Diego, CA 92101 Exhibition hall：San Diego Convention Center Product range: Biochemical Sector: Biochemical instruments, medical analysis and diagnostic instruments, biopharmaceutical instruments, pharmaceuticals and diagnostics, protein/peptide synthesis systems, molecular biology instruments, amino acid sequencers, DNA synthesizers, ELISA readers, cellular biology instruments, biochemical engineering equipment, biotechnology equipment, fermentation equipment, extraction equipment, separation equipment, filtration equipment, sterilization devices, purification equipment, detection and control equipment, liquid handling equipment, pure water equipment, cleanroom equipment, and various consumables. Analytical Instruments: Electronic and optical microscopes, electron probes, optical analysis instruments, mass spectrometers, spectroscopes, chromatographs, spectrographs, spectrum analyzers, electrochemical analysis instruments, X-ray analysis instruments, thermal analysis instruments, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition analysis instruments, injection analysis instruments. Laboratory Equipment: Various weighing instruments, balances, weighing sensors, weighing display controllers, and related ...
- Source: drugdu
- 84
- October 22, 2024
RNA editing pioneers fought a comeback

This is the title of an article published in Nauter in February this year (Move over, CRISPR: RNA-editing therapies pick up steam). RNA editing technology, which is coming to the fore, is seen as a potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer met. After years of silence, a counterattack driven by clinical data is taking place. On October 16, Wave ...
- Source: drugdu
- 75
- October 19, 2024
Let’s go to Europe to seek gold

It is a general trend for pharmaceutical companies to go overseas, and the proposition of the times behind it is also advancing with the times. Under the new changes, how to re-examine the gold-mining places such as the United States, Europe, and Southeast Asia? Different countries and regions have different market sizes and policies and regulations. How to examine the pros and cons of the market and formulate a more suitable strategy for going overseas? Everything needs to be answered by the industry. At present, more and more signs show that pharmaceutical companies are no longer just focusing on the “fat meat” of the US market as in the past, and countries and regions such as Europe are becoming more and more important. After being hit repeatedly by the FDA, more and more PD-1s have moved to Europe and been approved for listing. Since the beginning of this year, domestic ...
- Source: drugdu
- 77
- October 10, 2024
Vietnam Medipharm Expo

Organiser：Ministry of Health of Vietnam Time：July 31 – August 2, 2025 Address：799 Đ. Nguyễn Văn Linh, Tân Phú, Quận 7, Hồ Chí Minh, Vietnam Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments Analytical Instruments: Optical analysis instruments, mass spectrometers, spectrographs, chromatographs, spectroscopes, frequency spectrum analyzers, electrochemical analysis instruments, ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, component analysis instruments, syringe analysis instruments, and other general analytical instruments Laboratory Equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical equipment, microscopes, optical ...
- Source: drugdu
- 96
- October 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.